Novartis Institutes for BioMedical Research
The Novartis Institutes for BioMedical Research (NIBR) is a global research organization committed to discovering innovative medicines that treat disease and improve health. NIBR scientists strive to improve the drug discovery process by pursuing a comprehensive, multi-disciplinary approach that integrates novel concepts and tools across multiple disease areas.
During the past several years, Novartis has been the company with the greatest number of new molecular entities approved by the US Food and Drug Administration. With an ongoing focus on diseases where medical needs remain unmet, NIBR scientists are working to ensure that Novartis maintains its strong pipeline and highly successful track record in innovative drug discovery.
Focus on patients
We are dedicated to creating value for patients.
